Trials / Active Not Recruiting
Active Not RecruitingNCT04174196
A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma
A Pilot Study Evaluating Lenalidomide and CC-486 in Combination With Radiotherapy For Patients With Plasmacytoma (LENAZART Study)
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate if the combination of CC-486 with lenalidomide and radiation therapy is a safe and effective treatment for plasmacytoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CC-486 | Participants will be treated with CC-486 and lenalidomide for 6 cycles |
| DRUG | Lenalidomide | Participants will be treated with CC-486 and lenalidomide for 6 cycles |
| RADIATION | Radiation Therapy | Radiation therapy will be initiated to the plasmacytoma after cycle 2 |
Timeline
- Start date
- 2019-11-19
- Primary completion
- 2026-11-19
- Completion
- 2026-11-19
- First posted
- 2019-11-22
- Last updated
- 2025-12-02
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04174196. Inclusion in this directory is not an endorsement.